Holen Sie sich die Stockscreener-App
92.45
0.77%
-0.72
Handel nachbörslich:
92.45
Schlusskurs vom Vortag:
$93.17
Offen:
$93.29
24-Stunden-Volumen:
531.90K
Relative Volume:
1.18
Marktkapitalisierung:
$4.39B
Einnahmen:
$291.49M
Nettoeinkommen (Verlust:
$-308.55M
KGV:
-20.41
EPS:
-4.53
Netto-Cashflow:
$-168.02M
1W Leistung:
+1.62%
1M Leistung:
-0.96%
6M Leistung:
+20.79%
1J Leistung:
+54.39%
1-Tages-Spanne:
$91.78
$95.00
1-Wochen-Bereich:
$91.78
$105.00
52-Wochen-Spanne:
$58.61
$105.00
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Firmenname
Axsome Therapeutics Inc
Sektor
Branche
Telefon
(212) 332-3241
Adresse
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
Vergleichen Sie AXSM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| AXSM | 92.45 | 4.39B | 291.49M | -308.55M | -168.02M | -4.53 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-06 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-04-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2024-01-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-08-08 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Eingeleitet | Piper Sandler | Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2022-09-07 | Fortgesetzt | Mizuho | Buy |
| 2021-08-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Eingeleitet | Berenberg | Buy |
| 2021-01-08 | Eingeleitet | Jefferies | Buy |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-09-29 | Eingeleitet | BofA Securities | Underperform |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-14 | Eingeleitet | Cowen | Outperform |
| 2019-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-16 | Bestätigt | Guggenheim | Buy |
| 2019-10-16 | Eingeleitet | Guggenheim | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-28 | Eingeleitet | SunTrust | Buy |
| 2019-05-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-08 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-15 | Bestätigt | H.C. Wainwright | Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2015-12-15 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
Is It Too Late to Buy Viking Therapeutics Stock? - The Motley Fool
FY2024 EPS Estimates for AXSM Increased by Leerink Partnrs - MarketBeat
Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript - AOL
Axsome Therapeutics Inc (AXSM) Quarterly 10-Q Report - Quartzy
Axsome Advances Sleep Disorder Pipeline as Sunosi Prescriptions Increase in Q3 - Sleep Review
Equities Analysts Offer Predictions for AXSM FY2027 Earnings - MarketBeat
William Blair Issues Pessimistic Outlook for AXSM Earnings - MarketBeat
Axsome stock price target increased, rating held on strong sales - Investing.com
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up - Yahoo Finance
Axsome stock price target increased, rating held on strong sales By Investing.com - Investing.com UK
Axsome Therapeutics stock hits 52-week high at $98.61 By Investing.com - Investing.com Nigeria
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2024 Earnings Call Transcript - Insider Monkey
Robert W. Baird Raises Axsome Therapeutics (NASDAQ:AXSM) Price Target to $116.00 - MarketBeat
Earnings call: Axsome Therapeutics reports record quarterly revenue By Investing.com - Investing.com Australia
Versor Investments LP Acquires New Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics’ Strong Q3 Growth Amidst Strategic Expansions - TipRanks
Axsome: Q3 Earnings Snapshot - Houston Chronicle
Earnings call: Axsome Therapeutics reports record quarterly revenue - Investing.com
Axsome Therapeutics stock hits 52-week high at $98.61 - Investing.com India
Axsome shares rise as Guggenheim lifts target to $135 By Investing.com - Investing.com UK
Axsome Therapeutics Q3 Earnings: Stay For Near Term Catalysts, Then Sell (AXSM) - Seeking Alpha
Axsome Therapeutics (NASDAQ:AXSM) Reaches New 52-Week HighShould You Buy? - MarketBeat
A Closer Look at 10 Analyst Recommendations For Axsome Therapeutics - Benzinga
Axsome Therapeutics Inc earnings beat by $0.04, revenue topped estimates - Investing.com
Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates - MSN
Axsome Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Axsome Therapeutics' (AXSM) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
(AXSM) Proactive Strategies - Stock Traders Daily
Privium Fund Management B.V. Grows Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Position Decreased by Lindbrook Capital LLC - MarketBeat
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024 - GlobeNewswire
Axsome Therapeutics to Present Breakthrough CNS Data Across 3 Major Disorders at NEI 2024 | AXSM Stock News - StockTitan
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Axsome Therapeutics (AXSM) to Release Earnings on Tuesday - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Position Trimmed by abrdn plc - MarketBeat
Assenagon Asset Management S.A. Lowers Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Analysts Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) Target Price at $124.64 - MarketBeat
(AXSM) Trading Advice - Stock Traders Daily
Upcoming Opportunities in Hypersomnia Therapeutics Market: - openPR
Axsome Therapeutics' (NASDAQ:AXSM) investors will be pleased with their impressive 257% return over the last five years - Simply Wall St
Major Depressive Disorder Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Otsuka Pharma, AbbVie, SAGE Therapeutics, Forest Laboratories, Axsome Therapeutics - The Globe and Mail
Major Depressive Disorder Market Expected to Experience Major - openPR
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024 - The Manila Times
Axsome Therapeutics Presents Data from Multiple Programs - GlobeNewswire
Values First Advisors Inc. Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Hennion & Walsh Asset Management Inc. Has $5.23 Million Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):